A novel hypothesis for atherosclerosis as a cholesterol sulfate deficiency syndrome

Theoretical Biology and Medical Modelling

Volumn 12, Issue 1, 2015, Pages

  Seneff, Stephanie ^a   Davidson, Robert M ^b   Lauritzen, Ann ^c   Samsel, Anthony ^d   Wainwright, Glyn ^e  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b PhyNet Inc   (United States)

^c Independent Researcher   (United States)

^d Research Scientist and Consultant   (United States)

^e Indepen Read of Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER; CHOLESTEROL SULFATE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; GLYCOSAMINOGLYCAN;

ATHEROSCLEROSIS; BIOLOGICAL MODEL; CIRCULATION; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY; SYNDROME;

ATHEROSCLEROSIS; BLOOD CIRCULATION; CHOLESTEROL ESTERS; EXTRACELLULAR MATRIX; GAMMA-GLUTAMYLTRANSFERASE; GLUTATHIONE; GLYCOSAMINOGLYCANS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; SYNDROME;

EID: 84931032083     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/s12976-015-0006-1     Document Type: Article

References (154)

1. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1, Part 2):293-8.
2. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793-808.
3. Chen Y, Ku H, Zhao L, Wheeler DC, Li L-C, Li Q, et al. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation. Arterioscler Thromb Vasc Biol. 2014;34:365-76.
4. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation. 2003;108:2154-69.
5. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148(2):209-14.
6. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199.
7. Koenig W. Inflammation and coronary heart disease: an overview. Cardiol Rev. 2001;9(1):31-5.
8. Kingston R, Kelly CJ, Murray P. The therapeutic role of taurine in ischaemia-reperfusion injury. Curr Pharm Des. 2004;10(19):2401-10.
9. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55(2):648-58.
10. Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimbürger O, Lindholm B, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 2002;13 Suppl 1:S28.
11. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350(9075):430-6.
12. Ravnskov U, McCully KS. Infections may be causal in the pathogenesis of atherosclerosis. Am J Med Sci. 2012;344(5):391-4.
13. Mann GV. Effects of sulfur compounds on hypercholesteremia and growth in cysteine-deficient monkeys. Am J Clin Nutr. 1960;8:491-7.
14. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111-28.
15. Benavides GA, Squadrito GL, Mills RW, Patel HD, Isbell TS, Patel RP, et al. Hydrogen sulfide mediates the vasoactivity of garlic. Proc Natl Acad Sci U S A. 2007;104(46):17977-82.
16. Seneff S, Lauritzen A, Davidson R, Lentz-Marino L. Is endothelial nitric oxide synthase a moonlighting protein whose day job is cholesterol sulfate synthesis? Implications for cholesterol transport, diabetes and cardiovascular disease. Entropy. 2012;14:2492-530.
17. McCully KS. Chemical pathology of homocysteine. V. Thioretinamide, thioretinaco, and cystathionine synthase function in degenerative diseases. Ann Clin Lab Sci. 2011;41(4):300-12.
18. Grimes DS, Hindle E, Dyer T. Sunlight, cholesterol and coronary heart disease. Q J Med. 1996;89:579-89.
19. MacPherson A, Bacsó J. Relationship of hair calcium concentration to incidence of coronary heart disease. Sci Total Environ. 2000;255(1-3):11-9.
20. Wood AD, Secombes KR, Thies F, Aucott L, Black AJ, Mavroeidi A, et al. Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: A parallel-group, double-blind, placebo-controlled RCT. J Clin Endocrinol Metab. 2012;97(10):3557-68.
21. Tian Q-Y, Sun D-H, Zhao M-G, Zhang W-H. Inhibition of nitric oxide synthase (NOS) underlies aluminum-induced inhibition of root elongation in Hibiscus moscheutos. New Phytol. 2007;174(2):322-31.
22. Marletta MA. Nitric oxide synthase: aspects concerning structure and catalysis. Cell. 1994;78(6):927-30.
23. Jeffery EH, Jansen HT, Dellinger JA. In viva interactions of aluminum with hepatic cytochrome P-450 and metallothionein. Fundam Appl Toxicol. 1987;8:541-8.
24. Alexidis AN, Rekka EA, Kourounakis PN. Influence of mercury and cadmium intoxication on hepatic microsomal CYP2E and CYP3A subfamilies. Res Commun Mol Pathol Pharmacol. 1994;85(1):67-72.
25. Hesham M, Korashy HM, El-Kadi AO. Modulation of TCDD-mediated induction of cytochrome P450 1A1 by mercury, lead, and copper in human HepG2 cell line. Toxicol in Vitro. 2008;22(1):154-8.
26. Anwar-Mohamed A, El-Sherbeni AA, Kim SH, Althurwi HN, Zordoky BN, El-Kadi AO. Acute arsenic toxicity alters cytochrome P450 and soluble epoxide hydrolase and their associated arachidonic acid metabolism in C57Bl/6 mouse heart. Xenobiotica. 2012;42(12):1235-47.
27. Samsel A, Seneff S. Glyphosate's suppression of cytochrome P450 enzymes and amino acid biosynthesis by the gut microbiome: Pathways to modern diseases. Entropy. 2013;15:1416-63.
28. Samsel A, Seneff S. Glyphosate, pathways to modern diseases II: Celiac sprue and gluten intolerance. Interdiscip Toxicol. 2013;6(4):159-84.
29. Meredith PA, Campbell BC, Moore MR, Goldberg A. The effects of industrial lead poisoning on cytochrome P450 mediated phenazone (antipyrine) hydroxylation. Eur J Clin Pharmacol. 1977;12(3):235-9.
30. Strott CA, Higashi Y. Cholesterol sulfate in human physiology: what's it all about? J Lipid Res. 2003;44:1268-78.
31. Hobkirk R. Steroid sulfotransferases and steroid sulfate sulfatases: characteristics and biological roles. Can J Biochem Cell Biol. 1985;63(11):1127-44.
32. Bergner EA, Shapiro LJ. Increased cholesterol sulfate in plasma and red blood cell membranes of steroid sulfatase deficient patients. J Clin Endocrinol Metab. 1981;53(1):221-3.
33. Xu L, Shen S, Ma Y, Kim JK, Rodriguez-Agudo D, Heuman DM, et al. 25-Hydroxycholesterol-3-sulfate attenuates inflammatory response via PPAR signaling in human THP-1 macrophages. Am J Physiol Endocrinol Metab. 2012;302(7):E788-99.
34. Ma Y, Xu L, Rodriguez-Agudo D, Li X, Heuman DM, Hylemon PB, et al. 25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway. Am J Physiol Endocrinol Metab. 2008;295:E1369-79.
35. Ren S, Li X, Rodriguez-Agudo D, Gil G, Hylemon P, Pandak WM. Sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes. Biochem Biophys Res Commun. 2007;360:802-8.
36. Kereiakes DJ, Topol EJ, George BS, Stack RS, Abbottsmith CW, Ellis S, et al. Myocardial infarction with minimal coronary atherosclerosis in the era of thrombolytic reperfusion. J Am Coll Cardiol. 1991;17:304-12.
37. Avila JL, Rojas M, Avila A. Cholesterol sulphate-reactive autoantibodies are specifically increased in chronic chagasic human patients. Clin Exp Immunol. 1996;103:40-6.
38. Freitas HFG, Chizzola PR, Paes AT, Lima ACP, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease. Int J Cardiol. 2005;102(2):239-47.
39. Laranja FS, Dias E, Nobrega G, Miranda A. Chagas' disease: a clinical, epidemiologic, and pathologic study. Circulation. 1956;14:1035-60.
40. Collard CD, Gelman S. Pathophysiology, clinical manifestations, and prevention of IschemiaReperfusion injury. Anesthesiology. 2001;94(6):1133-8.
41. Seal JB, Gewertz BL. Vascular dysfunction in ischemia-reperfusion injury. Ann Vasc Surg. 2005;19:572-84.
42. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M. The two faces of IKK and NF-κB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med. 2003;9:575-81.
43. Reitsma S, Slaaf DW, Vink H, van Zandvoort MAMJ, oude Egbrink MGA. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch Eur J Physiol. 2007;454:345-59.
44. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005;97:512-23.
45. Birbrair A, Zhang T, Wang Z-M, Messi ML, Mintz A, Delbono O. Pericytes at the intersection between tissue regeneration and pathology. Clin Sci (Lond). 2015;128(2):81-93.
46. Abramsson A, Kurup S, Busse M, Yamada S, Lindblom P, Schallmeiner E, et al. Defective N-sulfation of heparan sulfate proteoglycans limits PDGF-BB binding and pericyte recruitment in vascular development. Genes Dev. 2007;21:316-31.
47. Malojčic G, Glockshuber R. The PAPS-independent aryl sulfotransferase and the alternative disulfide bond formation system in pathogenic bacteria. Antioxid Redox Signal. 2010;13:1247-59.
48. Grobe K, Ledin J, Ringvall M, Holmborn K, Forsberg E, Esko JD, et al. Heparan sulfate and development: Differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochim Biophys Acta. 2002;1573:209-15.
49. Davidson RM, Seneff S. The initial common pathway of inflammation, disease, and sudden death. Entropy. 2012;14:1399-442.
50. Davidson RM, Lauritzen A, Seneff S. Biological water dynamics and entropy: a biophysical origin of cancer and other diseases. Entropy. 2013;15(9):3822-76.
51. Wall S. The history of electrokinetic phenomena. Curr Opin Colloid Interface Sci. 2010;15:119-24.
52. Ball P. Water as an active constituent in cell biology. Chem Rev. 2008;108:74-108.
53. Ball P. Nanobubbles are not a superficial matter. Chem Phys Chem. 2013;13:2173-7.
54. Fogarty AC, Duboue-Dijon E, Sterpone F, Hynes JT, Laage D. Biomolecular hydration dynamics: a jump model perspective. Chem Soc Rev. 2013;42:5672-83.
55. Pollack GH. Cells, gels and the engines of life. Ebner and Sons: New York, NY, USA; 2001.
56. Pollack GH. The fourth phase of water: beyond solid, liquid, and vapor. 1st ed. New York, NY, USA: Ebner & Sons; 2013.
57. Guo F, Friedman JM. Charge density-dependent modifications of hydration shell waters by Hofmeister ions. J Am Chem Soc. 2009;131:11010-8.
58. Tielrooij KJ, Garcia-Araez N, Bonn M, Bakker HJ. Cooperativity in ion hydration. Science. 2010;328:10069.
59. Ling GN. A revolution in the physiology of the living cell. Krieger Pub. Co: Malibar, FL USA; 1992.
60. Ling GN. A new theoretical foundation for the polarized-oriented multilayer theory of cell water and for inanimate systems demonstrating long-range dynamic structuring of water molecules. Physiol Chem Phys Med NMR. 2003;35(2):91-130.
61. Dahlke EE, Olson RM, Leverentz HR, Truhlar DG. Assessment of the accuracy of density functionals for prediction of relative energies and geometries of low-lying isomers of water hexamers. J Phys Chem A. 2008;112:3976-84.
62. Del Giudice E, Tedeschi A, Vitiello G, Voeikov V. Coherent structures in liquid water close to hydrophilic surfaces. J Phys Conf Ser. 2013;442:012-28.
63. Preparata G. QED coherence and matter. Singapore: World Scientific; 1995.
64. Duignan TT, Parsons DF, Ninham BW. A continuum solvent model of the multipolar dispersion solvation energy. J Phys Chem B. 2013;117:9412-20.
65. Doshi DA, Watkins EB, Israelachvili JN, Majewski J. Reduced water density at hydrophobic surfaces: effect of dissolved gases. Proc Natl Acad Sci U S A. 2005;102:9458-62.
66. Shatalov VM. Mechanism of the biological impact of weak electromagnetic fields and the in vitro effects of blood degassing. Biophysics. 2012;57:808-13.
67. Bunkin NF, Ninham BW, Ignatiev PS, Kozlov VA, Shkirin AV, Starosvetskij AV. Long-living nanobubbles of dissolved gas in aqueous solutions of salts and erythrocyte suspensions. J Biophotonics. 2011;4:150-64.
68. Wang R. Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J. 2002;16(13):1792-8.
69. Grant D, Long WF, Moffat CF, Williamson FB. A study of Ca(2+)-heparin complex-formation by polarimetry. Biochem J. 1992;282(Pt 2):601-4.
70. O'Brien JT, Prell JS, Bush MF, Williams ER. Sulfate ion patterns water at long distance. J Am Chem Soc. 2010;132:8248-9.
71. Yoo H, Paranji R, Pollack GH. Impact of hydrophilic surfaces on interfacial water dynamics probed with NMR spectroscopy. J Phys Chem Lett. 2011;2(6):532-6.
72. Rohani M, Pollack GH. Flow through horizontal tubes submerged in water in the absence of a pressure gradient: mechanistic considerations. Langmuir. 2013;29:6556-61.
73. Figueroa XA, Pollack GH. Exclusion zone formation from discontinuous Nafion surfaces. Int J Des Nat Ecodyn. 2011;6:286-96.
74. Bunkin NF, Ignatiev PS, Kozlov VA, Shkirin AV, Zakharov SD, Zinchenko AA. Studies of the phase states of water close to Nafion interface. Water. 2013;4:129-54.
75. Zhao Q, Zheng J, Chai B, Pollack GH. Unexpected effect of light on colloidal crystal spacing. Langmuir. 2008;24:1250-5.
76. Trivedi DP, Hallock KJ, Bergethon PR. Electric fields caused by blood flow modulate vascular endothelial electrophysiology and nitric oxide production. Bioelectromagnetics. 2013;34(1):22-30.
77. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. PNAS USA. 1987;84(24):9265-9.
78. Zhao C, Yang C. Electroosmotic flows of non-Newtonian power law fluids in a cylindrical microchannel. Electrophoresis. 2013;34:662-7.
79. Delgado AV, González-Caballero F, Hunter RJ, Koopal LK, Lyklema J. Measurement and interpretation of electrokinetic phenomena. Pure Appl Chem. 2005;77:1753-805.
80. Wander K, Shell-Duncan B, McDade TW. Evaluation of iron deficiency as a nutritional adaptation to infectious disease: an evolutionary medicine perspective. Am J Hum Biol. 2009;21(2):172-9.
81. Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ. 2008;179(4):333-7.
82. Forbes MS, Thornhill BA, Park MH, Chevalier RL. Lack of endothelial nitric-oxide synthase leads to progressive focal renal injury. Am J Pathol. 2007;170(1):87-99.
83. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783-8.
84. Bleau G, Bodley FH, Longpré J, Chapdelaine A, Roberts KD. Cholesterol sulfate. I. Occurrence and possible biological functions as an amphipathic lipid in the membrane of the human erythrocyte. Biochim Biophys Acta Biomembranes. 1974;352(1):1-9.
85. Butt H-J, Graf K, Kappl M. Physics and chemistry of interfaces. Weinheim, Germany: Wiley-VCH Verlag & Co. KGaA; 2003.
86. Bharti RP, Harvie DJE, Davidson MR. Electroviscous effects in steady fully developed flow of a power-law liquid through a cylindrical microchannel. Int J Heat Fluid Flow. 2009;30:804-11.
87. Brust M, Schaefer C, Doerr R, Pan L, Garcia M, Arratia PE, et al. Rheology of human blood plasma: viscoelastic versus newtonian behavior. Phys Rev Lett. 2013;110:078305.
88. Guyton AC, Hall JE. Textbook of medical physiology. 10th ed. Philadelphia: W. B. Saunders Company; 2000. p. 162 and 382.
89. Banquy X, Burdynska J, Lee DW, Matyjaszewski K, Israelachvili J. Bioinspired bottle-brush polymer exhibits low friction and Amontons-like behavior. J Am Chem Soc. 2014;136:6199-202.
90. Rowlinson JS, Widom B. Molecular theory of capillarity. Oxford, UK: Oxford Press; 1989.
91. Sherman IA. Interfacial tension effects in the microvasculature. Microvasc Res. 1981;22:296-307.
92. Burcik EJ, Vaughn CR. The effect of pH on the rate of surface tension lowering. J Colloid Sci. 1951;6:522-7.
93. Yoon R-H, Yordan JL. Zeta-potential measurements on microbubbles generated using various surfactants. J Colloid Interface Sci. 1986;113:430-8.
94. Hamlin BS, Ristenpart WD. Transient reduction of the drag coefficient of charged droplets via the convective reversal of stagnant caps. Phys Fluids. 2012;24(1):012101.
95. Colacicco G. Electrical potential at an oil/water interface. Nature. 1965;207:936-8.
96. Burton AC. On the physical equilibrium of the small blood vessels. Amer J Physiol. 1951;164:319-29.
97. Rodrigues SF, Granger DN. Role of blood cells in ischaemia reperfusion induced endothelial barrier failure. Cardiovascular Res. 2010;87:291-9.
98. Paka L, Kako Y, Obunike JC, Pillarisetti S. Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains: a potential mechanism for the anti-atherogenic actions of vascular apolipoprotein E. J Biol Chem. 1999;274:4816-23.
99. Fuda H, Javitt NB, Mitamura K, Ikegawa S, Strott CA. Oxysterols are substrates for cholesterol sulfotransferase. JLR. 2007;48:1343-52.
100. Yanai H, Javitt NB, Higashi Y, Fuda H, Strott CA. Expression of cholesterol sulfotransferase (SULT2B1b) in human platelets. Circulation. 2004;109(1):92-6.
101. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8(4):222-32.
102. Subbotin VM. Neovascularization of coronary tunica intima (DIT) is the cause of coronary atherosclerosis. Lipoproteins invade coronary intima via neovascularization from adventitial vasa vasorum, but not from the arterial lumen: a hypothesis. Theor Biol Med Model. 2012;9:11.
103. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013;33(7):1696-705.
104. Plager JE. The binding of androsterone sulfate, etiocholanolone sulfate, and dehydroisoandrosterone sulfate by human plasma protein. J Clin Invest. 1965;44:1234-9.
105. Iwasaki Y, Asai M, Yoshida M, Nigawara T, Kambayashi M, Nakashima N. Dehydroepiandrosterone-sulfate inhibits nuclear factor-κB-dependent transcription in hepatocytes, possibly through antioxidant ef-fect. J Clin Endocrinol Metab. 2004;89(7):3449-54.
106. Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JBL, Kastelein JJP, Stroes ESG. The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol. 2005;16(5):507-11.
107. Lamanna WC, Kalus I, Padva M, Baldwin RJ, Merry CL, Dierks T. The heparanome-the enigma of encoding and decoding heparan sulfate sulfation. J Biotechnol. 2007;129(2):290-307.
108. Gupta V, Grande-Allen KJ. Effects of static and cyclic loading in regulating extracellular matrix synthesis by cardiovascular cells. Cardiovasc Res. 2006;72:375-83.
109. Kennett EC, Chuang CY, Degendorfer G, Whitelock JM, Davies MJ. Mechanisms and consequences of oxidative damage to extracellular matrix. Biochem Soc Trans. 2011;39(5):1279-87.
110. Hauss WH, Junge-Hülsing G, Holländer HJ. Changes in metabolism of connective tissue associated with ageing and arterio-or atherosclerosis. J Atheroscler Res. 1962;2(1-2):50-61.
111. Hauss WH, Gerlach U, Junge-Hülsing G, Themann H, Wirth W. Studies on the "nonspecific mesenchymal reaction" and the "transit zone" in myocardial lesions and atherosclerosis. Ann N Y Acad Sci. 1969;156(1):207-18.
112. Evanko SP, Angello JC, Wight TN. Formation of hyaluronan-and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:1004-13.
113. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52.
114. Tumova S, Woods A, Couchman JR. Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol. 2000;32(3):269-88.
115. Kruse R, Merten M, Yoshida K, Schmidt A, Völker W, Buddecke E. Cholesterol-dependent changes of glycosaminoglycan pattern in human aorta. Basic Res Cardiol. 1996;91(5):344-52.
116. Basta G, Schmidt AM, de Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63:582-92.
117. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Rev Cardiol. 2008;5:338-49.
118. Manna P, Jain SK. Hydrogen sulfide and L-cysteine increase phosphatidylinositol 3,4,5-trisphosphate (PIP3) and glucose utilization by inhibiting phosphatase and tensin homolog (PTEN) protein and activating phosphoinositide 3-kinase (PI3K)/serine/threonine protein kinase (AKT)/protein kinase Cζ/λ (PKCζ/λ) in 3T3l1 adipocytes. J Biol Chem. 2011;286(46):39848-59.
119. Lewandowska M, Sirko A. Recent advances in understanding plant response to sulfur-deficiency stress. Acta Biochim Pol. 2008;55(3):457-71.
120. Rennenberg H, Schmitz K, Bergmann L. Long-distance transport of sulfur in Nicotiana tabacum. Planta. 1979;147:57-62.
121. Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension. 2000;36:142-6.
122. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol. 1995;142:699-708.
123. Emdin M, Passino C, Michelassi C, Titta F, L'Abbate A, Donato L, et al. Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. Eur Heart J. 2001;22:1802-7.
124. Claessen H, Brenner H, Drath C, Arndt V. Gamma-glutamyltransferase and disability pension: a cohort study of construction workers in Germany. Hepatology. 2010;51(2):482-90.
125. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127-33.
126. Corti A, Franzini M, Paolicchi A, Pompella A. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res. 2010;30:1169-82.
127. Onat A, Can G, Örnek E, Çiek G, Ayhan E, Dogan Y. Serum-glutamyltransferase:independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring). 2012;20(4):842-8.
128. Marubayashi S, Dohi K, Yamada K, Kawasaki T. Changes in the levels of endogenous coenzyme Q homologs, -tocopherol, and glutathione in rat liver after hepatic ischemia and reperfusion, and the effect of pretreatment with coenzyme Q10. Biochim Biophys Acta General Subjects. 1984;797(1):1-9.
129. Anderson MF, Sims NR. The effects of focal ischemia and reperfusion on the glutathione content of mitochondria from rat brain subregions. J Neurochem. 2002;81:541-9.
130. Toshikuni N, Asaji T, Nakanishi Y, Nagasawa S-Y, Uenishi H, Tsutsumi M. Elevated serum gamma-glutamyl transpeptidase levels and fatty liver strongly predict the presence of carotid plaque. J Atheroscler Thromb. 2015. [ePub ahead of print].
131. Paolicchi A, Dominici S, Pieri L, Maellaro E, Pompella A. Glutathione catabolism as a signaling mechanism. Biochem Pharmacol. 2002;64:1027-35.
132. Stark AA, Pagano DA, Arad A, Siskindovitch S, Zeiger E. Effect of pH on mutagenesis by thiols in Salmonella typhimurium TA102. Mutat Res. 1989;224:89-94.
133. Spear N, Aust SD. Thiol-mediated NTA-Fe(III) reduction and lipid peroxidation. Arch Biochem Biophys. 1994;312(1):198-202.
134. Joseph CA, Maroney MJ. Cysteine dioxygenase: structure and mechanism. Chem Commun (Camb.). 2007;3338-3349.
135. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24(4):704-9.
136. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202-6.
137. McCully KS. Homocysteine, folate, vitamin b6, and cardiovascular disease. JAMA. 1998;279(5):392-3.
138. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev. 2002;54:599-618.
139. Steed MM, Tyagi N, Sen U, Schuschke DA, Joshua IG, Tyagi SC. Functional consequences of the collagen/elastin switch in vascular remodeling in hyperhomocysteinemic wild-type, eNOS-/-, and iNOS-/- mice. Am J Physiol Lung Cell Mol Physiol. 2010;299(3):L301-11.
140. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Zaid A, Giannogonas P, et al. cGMP-dependent protein kinase contributes to hydrogen sulfide-stimulated vasorelaxation. PLoS One. 2012;7(12):e53319.
141. Qiao W, Chaoshu T, Hongfang J, Junbao D. Endogenous hydrogen sulfide is involved in the pathogenesis of atherosclerosis. Biochem Biophys Res Commun. 2010;396:18-26.
142. Xu S, Liu Z, Liu P. Targeting hydrogen sulfide as a promising therapeutic strategy for atherosclerosis. Int J Cardiol. 2014;172:313-7.
143. Lefer DJ. A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide. Proc Natl Acad Sci U S A. 2007;104:179078.
144. Liu Y-H, Lu M, Hu L-F, Wong PT, Webb GD, Bian J-S. Hydrogen sulfide in the mammalian cardiovascular system. Antioxid Redox Signal. 2012;17(1):141-85.
145. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J. 2001;20:6008-16.
146. Fu M, Zhang W, Wu L, Yang G, Lia H, Wang R. Hydrogen sulfide (H2S) metabolism in mitochondria and its regulatory role in energy production. Proc Natl Acad Sci U S A. 2012;109(8):2943-8.
147. Olson KR, Deleon ER, Gao Y, Hurley K, Sadauskas V, Batz C, et al. Thiosulfate: a readily accessible source of hydrogen sulfide in oxygen sensing. Am J Physiol Regul Integr Comp Physiol. 2013;305:R592-603.
148. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853-906.
149. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S-60.
150. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;369(9339):1071-3.
151. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-77.
152. Bnaa KH, Njlstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-88.
153. Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300:795-804.
154. Peerschke EI, Yin W, Ghebrehiwet B. Platelet mediated complement activation. Adv Exp Med Biol. 2008;632:81-91.